Filgrastim Hospira (US) + U.S.-approved Neupogen®
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neutropenia (Low White Blood Cell Count)
Conditions
Neutropenia (Low White Blood Cell Count)
Trial Timeline
Mar 1, 2016 → Jun 1, 2016
NCT ID
NCT02766634About Filgrastim Hospira (US) + U.S.-approved Neupogen®
Filgrastim Hospira (US) + U.S.-approved Neupogen® is a phase 1 stage product being developed by Pfizer for Neutropenia (Low White Blood Cell Count). The current trial status is completed. This product is registered under clinical trial identifier NCT02766634. Target conditions include Neutropenia (Low White Blood Cell Count).
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02766634 | Phase 1 | Completed |
Competing Products
20 competing products in Neutropenia (Low White Blood Cell Count)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Approved | 85 |
| pegfilgrastim | Kyowa Kirin | Phase 2 | 52 |
| HHPG-19K Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| caspofungin acetate + Comparator: AmBisome | Merck | Phase 2 | 52 |
| Imipenem + Imipenem | Merck | Approved | 85 |
| Posaconazole IV solution + Posaconazole powder for oral suspension | Merck | Phase 1 | 33 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Approved | 85 |
| Ceftolozane-tazobactam IV | Merck | Approved | 85 |
| Daptomycin + Daptomycin | Merck | Phase 3 | 77 |
| pegfilgrastim | Amgen | Phase 3 | 76 |
| Neulasta (pegfilgrastim) | Amgen | Approved | 84 |
| Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®) | Gilead Sciences | Approved | 84 |
| Filgrastim Hospira (US) + US-approved Neupogen® | Pfizer | Phase 1 | 32 |
| HSP-130 + US-approved Neulasta + EU-approved Neulasta | Pfizer | Phase 1 | 32 |
| linezolid + vancomycin | Pfizer | Phase 3 | 76 |
| Anidulafungin | Pfizer | Phase 1/2 | 40 |
| Nivestim® | Pfizer | Pre-clinical | 22 |
| Antibacterial agent for the treatment of febrile neutropenia | Pfizer | Pre-clinical | 22 |
| Voriconazole | Pfizer | Phase 1/2 | 40 |
| ciprofloxacin + cefepime | Bayer | Phase 3 | 74 |